🕐 --:--
-- --
عاجل
⚡ عاجل: كريستيانو رونالدو يُتوّج كأفضل لاعب كرة قدم في العالم ⚡ أخبار عاجلة تتابعونها لحظة بلحظة على خبر ⚡ تابعوا آخر المستجدات والأحداث من حول العالم
⌘K
AI مباشر | -- مشاهد مباشر
881,878 مقال 404 مصدر نشط 228 قناة مباشرة 3,940 خبر اليوم
آخر تحديث: منذ ثانيتين

Novo weight-loss drug may preserve lean body mass better than Lilly’s, study finds

صحة
ARY News EN
2026/04/16 - 20:30 511 مشاهدة
تحليل ذكي | AI Editorial Analysis
جاري تحليل المقال...
HealthInternationalNovo weight-loss drug may preserve lean body mass better than Lilly's, study findsBy Reuters -Apr 17, 2026Eli Lilly’s  GLP-1 ​drug tirzepatide yields greater weight loss on average than Novo Nordisk’s  semaglutide, but at a greater expense ‌to muscles and connective tissues, according to a study published this week ahead of peer review. Tirzepatide, sold as Zepbound and Mounjaro, and semaglutide, under the brand names Wegovy and Ozempic, have become wildly popular for weight loss and have demonstrated other health benefits, such as heart-protective properties. But ​there has been concern that they induce loss of muscle and other components of lean body mass along with ​fat. The researchers analyzed data on roughly 1,800 patients using tirzepatide and 6,200 using semaglutide. Tirzepatide was consistently ⁠associated with greater loss of lean body mass than semaglutide. Tirzepatide patients lost an average of 1.1% more lean body ​mass after three months and 2% after 12 months of continuous use, the analysis by Massachusetts-based data analytics firm nference found. “This ​suggests that patients shouldn’t simplistically be thinking, ‘I want to lose X amount of weight and I’ll go with the option that delivers greater weight loss,’” said study leader Venky Soundararajan of nference on the study data published online. Patients were tracked before and during treatment either with low radiation ​scans or with “smart” scales that estimate body fat percentage, muscle mass, bone mass, and other components. The study cannot explain why lean ​body mass loss was greater with tirzepatide, which mimics the hormones GLP-1 and GIP, compared with semaglutide, which only mimics GLP-1. Mimicking the ‌hormones ⁠slows digestion and makes patients feel full. A Novo spokesperson did not comment on the current study but said changes in muscle mass did not significantly differ between semaglutide and placebo groups in clinical trials, and physical function was preserve...
المصدر: ARY News EN | Source: ARY News EN

ملاحظة تحريرية | Editorial Note: نُشر هذا المقال في الأصل بواسطة ARY News EN. خبر (Khabr) هي منصة إعلامية أردنية مرخّصة تعمل بالذكاء الاصطناعي. نضيف قيمة تحريرية من خلال: تحليل ذكي للأخبار، ملخصات تلقائية، رواية صوتية بالذكاء الاصطناعي، ترجمة متعددة اللغات، وتدقيق الحقائق. هدفنا جعل الأخبار أكثر وضوحاً وسهولةً للقارئ العربي.

This article was originally published by ARY News EN. Khabr is a licensed Jordanian AI-powered news platform (Registration #82086). We add editorial value through: AI-powered news analysis, automated summaries, AI audio narration, multi-language translation (Arabic, English, French, Turkish), and AI fact-checking. Our mission is to make news more accessible and understandable for Arabic-speaking audiences worldwide.

مشاركة:

المزيد عن صحة | More on Health

هذا الخبر ضمن تغطية خبر لقسم صحة. نقدّم لك تحليلات ذكية وملخصات يومية لأهم الأخبار من مصادر موثوقة متعددة. المصدر: ARY News EN. يوجد 6 مقالات مرتبطة بهذا الموضوع.

This article is part of Khabr's coverage of Health. We provide AI-powered analysis, summaries, and multi-source aggregation to keep you informed. Source: ARY News EN. Tags: weight loss, drug study, health research.

مقالات ذات صلة

AI
يا هلا! اسألني أي شي 🎤
🔍
FREE Free 1GB Internet + Free International Calls

$1 trial — eSIM in 190+ countries — No roaming charges

Download Free